UK Markets closed

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
109.00-0.17 (-0.16%)
As of 02:59PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close109.17
Open110.39
Bid0.00 x 0
Ask0.00 x 0
Day's range104.94 - 110.39
52-week range64.72 - 118.68
Volume115,138
Avg. volume14,743
Market cap255.484B
Beta (5Y monthly)0.27
PE ratio (TTM)37.33
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.48 (1.44%)
Ex-dividend date16 Aug 2021
1y target estN/A
All
News
  • Globe Newswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 29 November 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021. Under the programm

  • Globe Newswire

    Novo Nordisk announces impact from Volume Based Procurement for insulin in China

    Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®. Novo Nordisk currently expects an estimated negative impact on global sales growth of a

  • Globe Newswire

    Ozempic® 2.0 mg recommended for approval for the treatment of type 2 diabetes by the European Medicines Agency

    Bagsværd, Denmark, 12 November 2021 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults. The positive